JP7146286B2 - 多発性硬化症の進行を検出する、サブタイプ分類する、および／または評価するための、診断用バイオマーカー - Google Patents

多発性硬化症の進行を検出する、サブタイプ分類する、および／または評価するための、診断用バイオマーカー Download PDF

Info

Publication number
JP7146286B2
JP7146286B2 JP2019562415A JP2019562415A JP7146286B2 JP 7146286 B2 JP7146286 B2 JP 7146286B2 JP 2019562415 A JP2019562415 A JP 2019562415A JP 2019562415 A JP2019562415 A JP 2019562415A JP 7146286 B2 JP7146286 B2 JP 7146286B2
Authority
JP
Japan
Prior art keywords
subject
antigens
group
antigen
autoantibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519895A (ja
JP2020519895A5 (https=
Inventor
ロバート ジー． ナーゲル
Original Assignee
ローワン・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローワン・ユニバーシティ filed Critical ローワン・ユニバーシティ
Publication of JP2020519895A publication Critical patent/JP2020519895A/ja
Publication of JP2020519895A5 publication Critical patent/JP2020519895A5/ja
Application granted granted Critical
Publication of JP7146286B2 publication Critical patent/JP7146286B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
JP2019562415A 2017-05-10 2018-05-10 多発性硬化症の進行を検出する、サブタイプ分類する、および／または評価するための、診断用バイオマーカー Active JP7146286B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504130P 2017-05-10 2017-05-10
US62/504,130 2017-05-10
PCT/US2018/032130 WO2018209126A1 (en) 2017-05-10 2018-05-10 Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis

Publications (3)

Publication Number Publication Date
JP2020519895A JP2020519895A (ja) 2020-07-02
JP2020519895A5 JP2020519895A5 (https=) 2021-07-26
JP7146286B2 true JP7146286B2 (ja) 2022-10-04

Family

ID=64104996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562415A Active JP7146286B2 (ja) 2017-05-10 2018-05-10 多発性硬化症の進行を検出する、サブタイプ分類する、および／または評価するための、診断用バイオマーカー

Country Status (5)

Country Link
US (3) US20210003570A1 (https=)
EP (1) EP3622291A4 (https=)
JP (1) JP7146286B2 (https=)
CA (1) CA3062763A1 (https=)
WO (1) WO2018209126A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110186962B (zh) * 2019-05-10 2021-06-25 天津大学 一种用于电容层析成像的不完整测量数据成像方法
BR112023001788A2 (pt) * 2020-08-03 2023-02-23 Prevail Therapeutics Inc Vetores aav que codificam parkina e usos da mesma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528799A (ja) 2010-05-13 2013-07-11 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 神経変性疾患の検知および診断のための診断用自己抗体プロファイル

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0902885A4 (en) 1996-05-16 2006-09-27 Affymetrix Inc SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS
ATE296898T1 (de) 1997-03-20 2005-06-15 Affymetrix Inc Iterative resequenzierung
US6201639B1 (en) 1998-03-20 2001-03-13 James W. Overbeck Wide field of view and high speed scanning microscopy
US6185030B1 (en) 1998-03-20 2001-02-06 James W. Overbeck Wide field of view and high speed scanning microscopy
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6218803B1 (en) 1999-06-04 2001-04-17 Genetic Microsystems, Inc. Position sensing with variable capacitance transducers
JP2004003989A (ja) 2002-03-15 2004-01-08 Affymetrix Inc 生物学的物質の走査のためのシステム、方法、および製品
US20050032074A1 (en) 2002-09-09 2005-02-10 Affymetrix, Inc. Custom design method for resequencing arrays
US7300788B2 (en) 2002-10-08 2007-11-27 Affymetrix, Inc. Method for genotyping polymorphisms in humans
CA2505515C (en) 2002-11-07 2013-08-27 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
US7317415B2 (en) 2003-08-08 2008-01-08 Affymetrix, Inc. System, method, and product for scanning of biological materials employing dual analog integrators
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
US9746482B2 (en) 2011-08-11 2017-08-29 Rowan University Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
US11446398B2 (en) * 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528799A (ja) 2010-05-13 2013-07-11 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 神経変性疾患の検知および診断のための診断用自己抗体プロファイル

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antigen Microarrays Identify Unique Serum Autoantibody Signatures in Clinical and Pathologic Subtypes of Multiple Sclerosis，Proceedings of the National Academy of Sciences of the United States of America，2008年，Vol.105, No.48，pp.18889-18894，DOI: 10.1073/pnas.0806310105

Also Published As

Publication number Publication date
WO2018209126A1 (en) 2018-11-15
US20220390447A1 (en) 2022-12-08
US12174187B2 (en) 2024-12-24
US20220390448A1 (en) 2022-12-08
EP3622291A1 (en) 2020-03-18
JP2020519895A (ja) 2020-07-02
CA3062763A1 (en) 2018-11-15
US20210003570A1 (en) 2021-01-07
EP3622291A4 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
JP6265507B2 (ja) 認知機能障害疾患のバイオマーカー及び当該バイオマーカーを用いる認知機能障害疾患の検出方法
US20120178637A1 (en) Biomarkers and methods for detecting alzheimer's disease
KR20080034851A (ko) 향상된 면역분석 방법
US11187708B2 (en) Early stage Parkinson's disease diagnostic kits and methods
WO2013023144A2 (en) Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
CN107709991B (zh) 用于诊断眼表炎症和干眼病的方法和装置
WO2014018903A1 (en) Autoantibody profiles in early detection and diagnosis of cancer
US12174187B2 (en) Methods for detecting multiple sclerosis (MS) diagnostic autoantibodies
US20210003590A1 (en) Marker sequences for diagnosing and stratifying systemic sclerosis patients
US20150087548A1 (en) Marker sequences for rheumatoid arthritis and use thereof
US20190293662A1 (en) Gfap derivatives for stroke diagnostics
JP4927825B2 (ja) 初期段階の心機能異常を診断または予測するための装置および方法
US11619632B2 (en) Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
US10408844B2 (en) Methods and compositions in diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis
US20160069883A1 (en) Biomarkers for detection of breast cancer
CN115209917A (zh) 用于检测花生过敏的测定法
CN116773825B (zh) 诊断急性川崎病的血液生物标志物和方法
HK40045405A (en) Methods and devices for diagnosing ocular surface inflammation and dry eye disease
HK40045405B (zh) 用於诊断眼表炎症和干眼病的方法和装置

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220913

R150 Certificate of patent or registration of utility model

Ref document number: 7146286

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250